Bergenbio ASA
OSE:BGBIO
Bergenbio ASA
EPS (Diluted)
Bergenbio ASA
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
B
|
Bergenbio ASA
OSE:BGBIO
|
EPS (Diluted)
-kr3
|
CAGR 3-Years
54%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
![]() |
Hofseth Biocare ASA
OSE:HBC
|
EPS (Diluted)
kr0
|
CAGR 3-Years
5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
6%
|
|
L
|
Lytix Biopharma AS
OSE:LYTIX
|
EPS (Diluted)
-kr1
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
![]() |
Arcticzymes Technologies ASA
OSE:AZT
|
EPS (Diluted)
kr0
|
CAGR 3-Years
-45%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
EPS (Diluted)
$0
|
CAGR 3-Years
-59%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
T
|
Thor Medical ASA
OSE:TRMED
|
EPS (Diluted)
kr0
|
CAGR 3-Years
66%
|
CAGR 5-Years
53%
|
CAGR 10-Years
26%
|
Bergenbio ASA
Glance View
BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Bergen, Hordaland. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) kinase inhibitors, small molecule AXL inhibitors, and antibody programs. Its flagship product is BGB324, an orally avaliable small molecule AXL kinase inhibitor. Inhibition of AXL kinase activity addresses an important mechanism in the evolution of cancer cell in terms of its aggressiveness, and focuses on creation of therapeutic options for cancer patients. The firm also performs a range of clinical trials for interested patients, primarily affected with acute myeloid leukemia and non-small cell lung cancer.
See Also
What is Bergenbio ASA's EPS (Diluted)?
EPS (Diluted)
-4
NOK
Based on the financial report for Dec 31, 2024, Bergenbio ASA's EPS (Diluted) amounts to -4 NOK.
What is Bergenbio ASA's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-3%
Over the last year, the EPS (Diluted) growth was 70%. The average annual EPS (Diluted) growth rates for Bergenbio ASA have been 54% over the past three years , -3% over the past five years .